Literature DB >> 27315352

Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study.

Jeffrey Cui1, Chi-Hua Chen2, Min-Tzu Lo2, Nicholas Schork3, Ricki Bettencourt1,4, Monica P Gonzalez1, Archana Bhatt1, Jonathan Hooker5, Katherine Shaffer1,6, Karen E Nelson7, Michelle T Long8, David A Brenner6, Claude B Sirlin5, Rohit Loomba9,10,11.   

Abstract

Nonalcoholic fatty liver disease is associated with metabolic risk factors including hypertension and dyslipidemia and may progress to liver fibrosis. Studies have shown that hepatic steatosis and fibrosis are heritable, but whether they have a significant shared gene effect is unknown. This study examined the shared gene effects between hepatic steatosis and fibrosis and their associations with metabolic risk factors. This was a cross-sectional analysis of a prospective cohort of well-characterized, community-dwelling twins (45 monozygotic, 20 dizygotic twin pairs, 130 total subjects) from southern California. Hepatic steatosis was assessed with magnetic resonance imaging-proton density fat fraction and hepatic fibrosis with magnetic resonance elastography. A standard bivariate twin additive genetics and unique environment effects model was used to estimate the proportion of phenotypic variance between two phenotypes accounted for by additive genetic effects and individual-specific environmental effects. Genetic correlations estimated from this model represent the degree to which the genetic determinants of two phenotypes overlap. Mean (± standard deviation) age and body mass index were 47.1 (±21.9) years and 26.2 (±5.8) kg/m2 , respectively. Among the cohort, 20% (26/130) had hepatic steatosis (magnetic resonance imaging-proton density fat fraction ≥5%), and 8.2% (10/122) had hepatic fibrosis (magnetic resonance elastography ≥3 kPa). Blood pressure (systolic and diastolic), triglycerides, glucose, homeostatic model assessment of insulin resistance, insulin, hemoglobin A1c, and low high-density lipoprotein had significant shared gene effects with hepatic steatosis. Triglycerides, glucose, homeostatic model assessment of insulin resistance, insulin, hemoglobin A1c, and low high-density lipoprotein had significant shared gene effects with hepatic fibrosis. Hepatic steatosis and fibrosis had a highly significant shared gene effect of 0.756 (95% confidence interval 0.716-1, P < 0.0001).
CONCLUSIONS: Genes involved with steatosis pathogenesis may also be involved with fibrosis pathogenesis. (Hepatology 2016;64:1547-1558).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2016        PMID: 27315352      PMCID: PMC5090982          DOI: 10.1002/hep.28674

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  42 in total

1.  Power of the classical twin design revisited.

Authors:  Peter M Visscher
Journal:  Twin Res       Date:  2004-10

2.  Heritability and genetic loci of fatty liver in familial combined hyperlipidemia.

Authors:  Martijn C G J Brouwers; Rita M Cantor; Naoko Kono; Jeong Lim Yoon; Carla J H van der Kallen; Monique A L Bilderbeek-Beckers; Marleen M J van Greevenbroek; Aldons J Lusis; Tjerk W A de Bruin
Journal:  J Lipid Res       Date:  2006-09-13       Impact factor: 5.922

3.  Hepatic histology in obese patients undergoing bariatric surgery.

Authors:  Mariana Machado; Pedro Marques-Vidal; Helena Cortez-Pinto
Journal:  J Hepatol       Date:  2006-07-25       Impact factor: 25.083

4.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

5.  Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.

Authors:  Jeffrey D Browning; Lidia S Szczepaniak; Robert Dobbins; Pamela Nuremberg; Jay D Horton; Jonathan C Cohen; Scott M Grundy; Helen H Hobbs
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

6.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

Authors:  Renata Belfort; Stephen A Harrison; Kenneth Brown; Celia Darland; Joan Finch; Jean Hardies; Bogdan Balas; Amalia Gastaldelli; Fermin Tio; Joseph Pulcini; Rachele Berria; Jennie Z Ma; Sunil Dwivedi; Russell Havranek; Chris Fincke; Ralph DeFronzo; George A Bannayan; Steven Schenker; Kenneth Cusi
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

7.  Long-term follow-up of patients with NAFLD and elevated liver enzymes.

Authors:  Mattias Ekstedt; Lennart E Franzén; Ulrik L Mathiesen; Lars Thorelius; Marika Holmqvist; Göran Bodemar; Stergios Kechagias
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

8.  Heritability of mammographic density, a risk factor for breast cancer.

Authors:  Norman F Boyd; Gillian S Dite; Jennifer Stone; Anoma Gunasekara; Dallas R English; Margaret R E McCredie; Graham G Giles; David Tritchler; Anna Chiarelli; Martin J Yaffe; John L Hopper
Journal:  N Engl J Med       Date:  2002-09-19       Impact factor: 91.245

9.  Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus.

Authors:  Nathalie C Leite; Gil F Salles; Antonio L E Araujo; Cristiane A Villela-Nogueira; Claudia R L Cardoso
Journal:  Liver Int       Date:  2008-04-01       Impact factor: 5.828

10.  Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease.

Authors:  Gary A Abrams; Sachin S Kunde; Audrey J Lazenby; Ronald H Clements
Journal:  Hepatology       Date:  2004-08       Impact factor: 17.425

View more
  27 in total

Review 1.  Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis.

Authors:  Johanna K DiStefano
Journal:  Cell Mol Life Sci       Date:  2020-06       Impact factor: 9.261

2.  Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.

Authors:  Cyrielle Caussy; Cynthia Hsu; Seema Singh; Shirin Bassirian; James Kolar; Claire Faulkner; Nikhil Sinha; Ricki Bettencourt; Naveen Gara; Mark A Valasek; Bernd Schnabl; Lisa Richards; David A Brenner; Alan F Hofmann; Rohit Loomba
Journal:  Aliment Pharmacol Ther       Date:  2018-12-02       Impact factor: 8.171

3.  Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.

Authors:  Cyrielle Caussy; Veeral H Ajmera; Puneet Puri; Cynthia Li-Shin Hsu; Shirin Bassirian; Mania Mgdsyan; Seema Singh; Claire Faulkner; Mark A Valasek; Emily Rizo; Lisa Richards; David A Brenner; Claude B Sirlin; Arun J Sanyal; Rohit Loomba
Journal:  Gut       Date:  2018-12-19       Impact factor: 23.059

4.  Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis.

Authors:  Cyrielle Caussy; Meera Soni; Jeffrey Cui; Ricki Bettencourt; Nicholas Schork; Chi-Hua Chen; Mahdi Al Ikhwan; Shirin Bassirian; Sandra Cepin; Monica P Gonzalez; Michel Mendler; Yuko Kono; Irine Vodkin; Kristin Mekeel; Jeffrey Haldorson; Alan Hemming; Barbara Andrews; Joanie Salotti; Lisa Richards; David A Brenner; Claude B Sirlin; Rohit Loomba
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

5.  Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography.

Authors:  Cyrielle Caussy; Meera Bhargava; Ida F Villesen; Natasja S Gudmann; Diana J Leeming; Morten A Karsdal; Claire Faulkner; Denny Bao; Amy Liu; Min-Tzu Lo; Ricki Bettencourt; Shirin Bassirian; Lisa Richards; David A Brenner; Chi-Hua Chen; Claude B Sirlin; Rohit Loomba
Journal:  Hepatology       Date:  2019-04-29       Impact factor: 17.425

6.  Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD.

Authors:  Cyrielle Caussy; Cynthia Hsu; Min-Tzu Lo; Amy Liu; Ricki Bettencourt; Veeral H Ajmera; Shirin Bassirian; Jonathan Hooker; Ethan Sy; Lisa Richards; Nicholas Schork; Bernd Schnabl; David A Brenner; Claude B Sirlin; Chi-Hua Chen; Rohit Loomba
Journal:  Hepatology       Date:  2018-05-20       Impact factor: 17.425

7.  Publisher Correction: The gut-liver axis and the intersection with the microbiome.

Authors:  Anupriya Tripathi; Justine Debelius; David A Brenner; Michael Karin; Rohit Loomba; Bernd Schnabl; Rob Knight
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-12       Impact factor: 46.802

8.  Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring.

Authors:  Michelle T Long; Ellen B Gurary; Joseph M Massaro; Jiantao Ma; Udo Hoffmann; Raymond T Chung; Emelia J Benjamin; Rohit Loomba
Journal:  Liver Int       Date:  2018-09-25       Impact factor: 5.828

9.  Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.

Authors:  Rohit Loomba; Victor Seguritan; Weizhong Li; Tao Long; Niels Klitgord; Archana Bhatt; Parambir Singh Dulai; Cyrielle Caussy; Richele Bettencourt; Sarah K Highlander; Marcus B Jones; Claude B Sirlin; Bernd Schnabl; Lauren Brinkac; Nicholas Schork; Chi-Hua Chen; David A Brenner; William Biggs; Shibu Yooseph; J Craig Venter; Karen E Nelson
Journal:  Cell Metab       Date:  2017-05-02       Impact factor: 27.287

10.  Nuclear lamina genetic variants, including a truncated LAP2, in twins and siblings with nonalcoholic fatty liver disease.

Authors:  Graham F Brady; Raymond Kwan; Peter J Ulintz; Phirum Nguyen; Shirin Bassirian; Venkatesha Basrur; Alexey I Nesvizhskii; Rohit Loomba; M Bishr Omary
Journal:  Hepatology       Date:  2018-03-24       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.